IDiyas

For the Inventor, By the Inventor

Wuppertal, Germany

Michael Matzke

USPTO Granted Patents = 32

Average Co-Inventor Count = 7.4

ph-index = 9

Forward Citations = 251(Granted Patents)


Company Filing History:

goldMedal31 out of 12,157 
 
Bayer Aktiengesellschaft
 patents
silverMedal1 out of 38 
 
Bayeraktiengesellschaft
 patents

Years Active: 1993-2004

Loading Chart...
32 patents (USPTO):
1. 6727279 - Arylsulphonamides and analogues (2004-04-27),
2. 6573278 - Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases (2003-06-03),
3. 6545050 - Aryl sulphonamide amino acid esters and analogues (2003-04-08),
4. 6525087 - Use of known agonists of the central cannabinoid receptor CB1 (2003-02-25),
5. 6469054 - Aryl sulphonamides and analogues (2002-10-22),
6. 6444828 - Method for preparing 1-alkyl-pyrazol-5-carboxylic acid esters III (2002-09-03),
7. 6432948 - USE OF 7-(2-OXA-5,8-DIAZABICYLCO[4.3.0]NON-8-YL)-QUINOLONE CARBOXYLIC ACID AND NAPHTHYRIDON CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF HELIOBACTER PYLORI INFECTIONS AND ASSOCIATED GASTRODUODENAL DISEASES (2002-08-13),
8. 6297386 - Method of preparing 1-alkyl-pyrazol-5-carboxylic acid esters (2001-10-02),
9. 6288081 - Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolone carboxylic acid and naphthyridone carboxylic acid derivatives for treating Helicobacter pylori infections and the gastroduodenal diseases associated therewith (2001-09-11),
10. 6284788 - Use of known agonists of the central cannabinoid receptor CB1 (2001-09-04),
11. 6262112 - Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases (2001-07-17),
12. 6133260 - Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic (2000-10-17),
13. 5962724 - High enantio-selective process for producing pure enantiomeric (1999-10-05),
14. 5935988 - Tolerability of pharmaceutically active .beta.-amino acids (1999-08-10),
15. 5776964 - Heterocyclically substituted phenylacetic acid derivatives and their use (1998-07-07),

Title: Innovator Spotlight: Michael Matzke - Pioneering Novel Treatment Solutions for Neurodegenerative Disorders

Introduction:

In the realm of innovative solutions for neurodegenerative disorders, inventor Michael Matzke from Wuppertal, Germany, stands out as a visionary with a remarkable track record. With 32 patents to his name, Matzke has been at the forefront of developing novel arylsulphonamides and analogues for the prophylaxis and treatment of various neurodegenerative conditions, including cerebral apoplexy, craniocerebral trauma, pain, and spasticity.

Latest Patents:

Matzke's latest patents showcase his dedication to advancing treatment options for neurodegenerative diseases. His inventions include arylsulphonamides and analogues, as well as aryl ether sulphonamides and their analogues, aimed at the treatment and prevention of a range of neurodegenerative disorders.

Career Highlights:

Michael Matzke is a key figure at Bayer Aktiengesellschaft, where he channels his expertise and passion for developing cutting-edge pharmaceutical solutions. His innovative approach and commitment to scientific excellence have earned him recognition as a leader in the field of neurodegenerative disease research.

Collaborations:

Matzke's collaborative spirit is evident through his work with esteemed colleagues such as Siegfried Raddatz and Klaus-Helmut Mohrs. Together, they form a dynamic team driving forward research and innovation in the treatment of neurodegenerative disorders.

Conclusion:

In conclusion, Michael Matzke's groundbreaking work in the field of neurodegenerative disorder treatment has significantly impacted the medical landscape. His relentless pursuit of novel solutions and collaborative efforts underscore his status as a pioneering inventor dedicated to transforming the lives of those affected by neurodegenerative diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…